Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience Inc. Announce Exit from Pharmaceutics International, Inc.
Pharmaceutics International, Inc. (Pii) has been acquired by Jabil Inc. (NYSE: JBL) in an all-cash transaction for an undisclosed amount. The sale marks the exit of a consortium of investors including Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Inc.
Pii, based in Hunt Valley, Maryland, is a contract development and manufacturing organization specializing in aseptic and sterile injectable pharmaceutical products. The company has provided development and manufacturing services for both NDA and aNDA products for nearly three decades, offering formulation capabilities across virtually all dosage forms and specializing in complex formulations.
The company operates on both a fee-for-service basis for pharmaceutical clients and a profit-share or royalty basis for marketing partners.
Pharmaceutics International, Inc. (Pii) è stata acquisita da Jabil Inc. (NYSE: JBL) in una transazione interamente in contante per un importo non divulgato. La vendita segna l’uscita di un consorzio di investitori tra cui Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital e Pharmascience Inc.
Pii, con sede a Hunt Valley, Maryland, è un'organizzazione di sviluppo e produzione a contratto specializzata in prodotti farmaceutici iniettabili asettici e sterili. L'azienda ha fornito servizi di sviluppo e produzione per prodotti sia NDA che aNDA per quasi tre decenni, offrendo capacità di formulazione in praticamente tutte le forme di dosaggio e specializzandosi in formulazioni complesse.
L'azienda opera sia su base di pagamento per servizio per i clienti farmaceutici che su base di condivisione degli utili o royalty per i partner di marketing.
Pharmaceutics International, Inc. (Pii) ha sido adquirida por Jabil Inc. (NYSE: JBL) en una transacción completamente en efectivo por un monto no divulgado. La venta marca la salida de un consorcio de inversores que incluye a Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital y Pharmascience Inc.
Pii, con sede en Hunt Valley, Maryland, es una organización de desarrollo y fabricación por contrato especializada en productos farmacéuticos inyectables asépticos y estériles. La empresa ha proporcionado servicios de desarrollo y fabricación tanto para productos NDA como aNDA durante casi tres décadas, ofreciendo capacidades de formulación en prácticamente todas las formas de dosificación y especializándose en formulaciones complejas.
La empresa opera tanto en base a tarifas por servicio para clientes farmacéuticos como en base a participación en beneficios o regalías para socios de comercialización.
Pharmaceutics International, Inc. (Pii)는 Jabil Inc. (NYSE: JBL)에 의해 비공식적인 금액으로 현금 거래로 인수되었습니다. 이 판매는 Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital 및 Pharmascience Inc.를 포함한 투자자 컨소시엄의 퇴장을 의미합니다.
메릴랜드주 헌트밸리에 본사를 두고 있는 Pii는 무균 및 멸균 주사 제형의 제약 제품을 전문으로 하는 계약 개발 및 제조 조직입니다. 이 회사는 거의 30년 동안 NDA 및 aNDA 제품에 대한 개발 및 제조 서비스를 제공했으며, 실제로 모든 제형 형태에 대한 제형 기능을 제공하고 복잡한 제형에 전문화되어 있습니다.
회사는 제약 고객을 위한 서비스 요금제와 마케팅 파트너를 위한 이익 분배 또는 로열티 기반으로 운영됩니다.
Pharmaceutics International, Inc. (Pii) a été acquis par Jabil Inc. (NYSE: JBL) dans une transaction entièrement en espèces pour un montant non divulgué. La vente marque le départ d'un consortium d'investisseurs, y compris Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital et Pharmascience Inc.
Pii, basé à Hunt Valley, Maryland, est une organisation de développement et de fabrication sous contrat spécialisée dans les produits pharmaceutiques injectables aseptiques et stériles. L'entreprise a fourni des services de développement et de fabrication pour des produits à la fois NDA et aNDA pendant près de trois décennies, offrant des capacités de formulation dans pratiquement toutes les formes posologiques et se spécialisant dans des formulations complexes.
L'entreprise opère à la fois sur une base de frais de service pour ses clients pharmaceutiques et sur une base de partage des bénéfices ou de redevances pour ses partenaires de marketing.
Pharmaceutics International, Inc. (Pii) wurde von Jabil Inc. (NYSE: JBL) in einer Bartransaktion zu einem nicht bekannt gegebenen Betrag erworben. Der Verkauf markiert den Ausstieg eines Konsortiums von Investoren, zu denen Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital und Pharmascience Inc. gehören.
Pii, mit Sitz in Hunt Valley, Maryland, ist eine Vertragsentwicklungs- und -produktionsorganisation, die sich auf aseptische und sterile injizierbare Arzneimittelprodukte spezialisiert hat. Das Unternehmen bietet seit fast drei Jahrzehnten Entwicklungs- und Produktionsdienste für NDA- und aNDA-Produkte an und bietet Formulierungsfähigkeiten in nahezu allen Darreichungsformen an und hat sich auf komplexe Formulierungen spezialisiert.
Das Unternehmen arbeitet sowohl auf einer Gebührenbasis für pharmazeutische Kunden als auch auf einer Gewinnbeteiligungs- oder Lizenzbasis für Marketingpartner.
- Acquisition by larger, NYSE-listed company Jabil Inc. (JBL)
- All-cash transaction structure indicates strong liquidity
- Strategic expansion into pharmaceutical manufacturing for Jabil
- Undisclosed transaction value creates uncertainty about deal terms
Insights
The acquisition of Pharmaceutics International (Pii) marks a significant strategic expansion for Jabil in the high-growth Contract Development and Manufacturing Organization (CDMO) sector. This deal is particularly noteworthy as it provides Jabil immediate access to specialized capabilities in aseptic and sterile injectable pharmaceutical manufacturing, a high-margin segment of the CDMO market.
The strategic value of this acquisition lies in three key areas: First, it diversifies Jabil's healthcare portfolio beyond medical devices into pharmaceutical manufacturing, positioning the company to capture a larger share of the expanding CDMO market, which is projected to grow at a CAGR of 7.5% through 2028. Second, Pii's three-decade expertise in complex formulations and regulatory compliance provides Jabil with valuable intellectual property and established relationships with pharmaceutical clients. Third, the deal presents significant cross-selling opportunities, allowing Jabil to offer end-to-end solutions to its existing healthcare customers.
From an operational perspective, the all-cash transaction structure suggests Jabil's strong financial position and confidence in immediate value creation. The integration of Pii's Hunt Valley facility adds a strategic East Coast presence to Jabil's manufacturing network, potentially improving operational efficiency and customer service capabilities. The acquisition is expected to be accretive to Jabil's healthcare segment margins, given Pii's focus on high-value, complex formulations and its mix of fee-for-service and profit-sharing revenue models.
Pii is a contract development and manufacturing business, based in
“We have greatly valued our partnership with Signet, Athyrium, Hildred and Pharmascience over the past decade,” said John Fowler, President and CEO of Pii. “Their collective operating expertise and breadth of experience across the healthcare ecosystem were invaluable in helping Pii strategically scale and enhance and expand our suite of capabilities. The firms’ Operating Partners played a critical role, working closely with management over an extended period of time to drive value at the company. All of us at Pii appreciate their long-standing commitment and support over the years. We are excited about our future and looking forward to building on our momentum and success with our new partners at Jabil.”
Sidley Austin LLP acted as legal counsel for Pii.
About Pharmaceutics International, Inc.
Pii is a privately held contract development and manufacturing organization providing dosage form development and manufacturing services to the global pharmaceutical industry. Headquartered in
About Signet Healthcare Partners
Signet Healthcare Partners is a leading provider of growth capital to innovative healthcare companies, with a focus on the pharmaceutical and medical device sectors. With over 25 years of experience, Signet has raised cumulative capital commitments exceeding
About Athyrium Capital Management
Athyrium is a specialized asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Athyrium advises funds with over
About Hildred Capital
Hildred Capital is a healthcare-focused private equity firm that specializes in operationally intensive, control-oriented investments in lower middle-market companies. Hildred partners with innovative and growth-oriented management teams to build high quality businesses. The Hildred team possesses extensive experience across the healthcare industry, and seeks to leverage its unique blend of strategic, financial, commercial and operational acumen to drive strategic growth and create value for its portfolio companies and investment partners. Hildred currently has more than
About Pharmascience Inc.
Founded in 1983, Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205394946/en/
Media:
Mike Geller
Prosek
mgeller@prosek.com
Source: Hildred Capital
FAQ
What is the acquisition price for Jabil's purchase of Pharmaceutics International?
What type of manufacturing capabilities does Pii bring to Jabil (JBL)?
How will the Pii acquisition affect Jabil's (JBL) pharmaceutical manufacturing presence?
What is Pii's business model that Jabil (JBL) is acquiring?
